Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | LPO | P22079 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL419709 | 0.73 | KMT2A (0.50) | KMT2AKCNH2KDM4EALDH1A1LMNA | |
| SCHEMBL18472183 | 0.71 | KCNH2 (0.33) | KMT2AKCNH2LPO | |
| SCHEMBL21452448 | 0.71 | KCNH2 (0.36) | KMT2AKCNH2LPO | |
| Hydrochloric Acid SCHEMBL16540240 | 0.71 | KMT2A (0.48) | KMT2AKCNH2KDM4EALDH1A1LMNA | |
| SCHEMBL27854351 | 0.71 | KCNH2 (0.33) | KMT2AKCNH2LPO | |
| SCHEMBL422085 | 0.71 | KCNH2 (0.33) | KMT2AKCNH2LPO | |
| SCHEMBL3732955 | 0.70 | KMT2A (0.36) | KMT2AKCNH2KDM4ELMNA | |
| Hydrochloric Acid SCHEMBL21110936 | 0.70 | KCNH2 (0.32) | KMT2AKCNH2 | |
| SCHEMBL28277861 | 0.69 | PARP1 (0.39) | KMT2AALDH1A1LMNA | |
| SCHEMBL18235319 | 0.68 | KCNH2 (0.31) | KMT2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230024240-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-01-26 | — | — | US | disclosed |
| US-20200354384-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2020-11-12 | — | — | US | disclosed |
| US-10626129-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190270759-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2019-09-05 | — | — | US | disclosed |
| US-20170342094-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2017-11-30 | — | — | US | disclosed |
| US-9777024-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2017-10-03 | — | — | US | disclosed |
| US-9777024-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2017-10-03 | — | — | US | disclosed |
| US-9670150-B2 | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators | ALLERGAN, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670150-B2 | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators | ALLERGAN, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160333043-A1 | E-Selectin Antagonists Modified By Macrocycle Formation to the Galactose | GLYCOMIMETICS, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160137672-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2016-05-19 | — | — | US | disclosed |
| US-9221843-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150119362-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2015-04-30 | — | — | US | disclosed |
| US-20130274230-A1 | (2-UREIDOACETAMIDO)ALKYL DERIVATIVES AS FORMYL PEPTIDE RECEPTOR 2 MODULATORS | ALLERGAN, INC. (US) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270759-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | KMT2A 3408/4885KCNH2 4420/4885KDM4E 1574/4885 |
| US-20130274230-A1 | (2-UREIDOACETAMIDO)ALKYL DERIVATIVES AS FORMYL PEPTIDE RECEPTOR 2 MODULATORS | FPR2, FPR3, FPR1 | KMT2A 4442/4885KCNH2 4632/4885KDM4E 4622/4885 |
| US-20200354384-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | KMT2A 3408/4885KCNH2 4420/4885KDM4E 1574/4885 |
| US-20230024240-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | KMT2A 3408/4885KCNH2 4420/4885KDM4E 1574/4885 |
| US-20150119362-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | KMT2A 2665/4885KCNH2 3251/4885KDM4E 1119/4885 |
| US-20160333043-A1 | E-Selectin Antagonists Modified By Macrocycle Formation to the Galactose | SELE, SELPLG, SELL | KMT2A 4499/4885KCNH2 4619/4885KDM4E 4024/4885 |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | KMT2A 3408/4885KCNH2 4420/4885KDM4E 1574/4885 |
| US-20170342094-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | KMT2A 3408/4885KCNH2 4420/4885KDM4E 1574/4885 |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | KMT2A 3408/4885KCNH2 4420/4885KDM4E 1574/4885 |
| US-10626129-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | KMT2A 3408/4885KCNH2 4420/4885KDM4E 1574/4885 |
| US-20160137672-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | KMT2A 2665/4885KCNH2 3251/4885KDM4E 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.